Biogen (BIIB)

285.40 -0.03 (0.01%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (1/29/20 *Est.)
- Spin-Off (3/31/17 *Est)

Latest Headlines

Charity to pay $4 million to resolve U.S. pharma kickback probe November 20, 2019 4:32 PM - StreetInsider Biogen (BIIB) New 'Mystery' Candidate BIIB101 Moves Into Clinic - RBC November 18, 2019 12:49 PM - StreetInsider Biogen (BIIB) Hits Low, Down 2.65% November 14, 2019 10:15 AM - StreetInsider Biogen (BIIB) Falls to Low, Down 2.4% November 13, 2019 9:53 AM - StreetInsider Alkermes (ALKS) Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY November 12, 2019 7:06 AM - StreetInsider Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™ November 12, 2019 7:00 AM - PR NewsWire UPDATE: SunTrust Starts Biogen (BIIB) at Buy November 12, 2019 4:31 AM - StreetInsider Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates November 6, 2019 7:46 AM - BizWire Biogen (BIIB) announced new proposed transaction with Samsung Bioepis November 6, 2019 7:40 AM - StreetInsider Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis November 6, 2019 7:30 AM - Globe NewsWire Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis November 6, 2019 7:30 AM - StreetInsider Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 November 4, 2019 4:30 PM - Globe NewsWire Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 November 4, 2019 4:30 PM - StreetInsider UPDATE: CORRECTION: Standpoint Research Downgrades Biogen (BIIB) to Hold from Buy November 1, 2019 1:01 PM - StreetInsider Pre-Open 10/30: (BGFV) (GDOT) (GEL) Higher (CYCN) (QUAD) (AMAG) Lower (more...) October 30, 2019 9:30 AM - StreetInsider Biogen (BIIB) and Alkermes ( ALKS) set to open higher after FDA approves VUMERITY for MS October 30, 2019 8:13 AM - StreetInsider Biogen (BIIB), Alkermes (ALKS) Report FDA Approval of VUMERITY (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:40 AM - StreetInsider Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:31 AM - StreetInsider Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:30 AM - Globe NewsWire Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:30 AM - PR NewsWire Bernstein Upgrades Biogen (BIIB) to Outperform, Boosts PT on Positive Aducanumab Risk-Reward October 29, 2019 4:28 PM - StreetInsider Biogen (BIIB) on Watch on Cautious Article October 28, 2019 11:14 AM - StreetInsider Biogen's secret campaign to bring its Alzheimer's drug back from the ashes October 25, 2019 7:08 AM - StreetInsider Stocks with Implied Volatility Movement October 25, 2019 4:23 AM - StreetInsider Biogen (BIIB) PT Raised to $290 at Goldman Sachs October 23, 2019 8:58 AM - StreetInsider Biogen (BIIB) PT Raised to $235 at BofA/Merrill Lynch October 23, 2019 8:54 AM - StreetInsider Biogen (BIIB) PT Raised to $335 at H.C. Wainwright October 23, 2019 7:45 AM - StreetInsider Biogen (BIIB) PT Raised to $300 at Cantor Fitzgerald on 30% Aducanumab POS October 23, 2019 7:31 AM - StreetInsider Biogen (BIIB) PT Raised to $325 at Cowen October 23, 2019 7:31 AM - StreetInsider Biogen (BIIB) PT Raised to $262 at Morgan Stanley October 23, 2019 7:11 AM - StreetInsider SVB Leerink Upgrades Biogen (BIIB) to Outperform October 23, 2019 7:11 AM - StreetInsider Biogen (BIIB) 30% Move is Justified - Nomura/Instinet October 23, 2019 6:39 AM - StreetInsider Biogen (BIIB) PT Raised to $260 at Credit Suisse October 23, 2019 6:36 AM - StreetInsider Biogen (BIIB) PT Raised to $315 at Citi October 23, 2019 6:13 AM - StreetInsider UPDATE: Guggenheim Upgrades Biogen (BIIB) to Buy October 23, 2019 6:10 AM - StreetInsider Biogen (BIIB) PT Raised to $305 at Canaccord Genuity October 23, 2019 5:14 AM - StreetInsider Biogen (BIIB) PT Raised to $297 at BMO Capital October 23, 2019 4:44 AM - StreetInsider Increasing unusual put option volume: GNW GDI BIIB GOSS CATM CTVA ODP GME October 23, 2019 4:36 AM - StreetInsider Stocks with Implied Volatility Movement October 23, 2019 4:24 AM - StreetInsider Biogen, Eisai revive plans for Alzheimer's drug, surprising market October 22, 2019 5:08 PM - StreetInsider Form 10-Q BIOGEN INC. For: Sep 30 October 22, 2019 4:14 PM - SEC Filing Biogen (BIIB) ALZ Drug Has 0% Chance of Winning Approval: Raymond James - Bloomberg October 22, 2019 3:50 PM - StreetInsider Biogen (BIIB) PT Raised to $310 at Jefferies October 22, 2019 1:45 PM - StreetInsider Biogen (BIIB) PT Raised to $249 at Wedbush October 22, 2019 12:44 PM - StreetInsider Biogen (BIIB) PT Raised to $296 at Stifel October 22, 2019 12:11 PM - StreetInsider Biogen (BIIB) PT Raised to $334 at Oppenheimer Amid Aducanuma News October 22, 2019 11:53 AM - StreetInsider Increasing unusual option volume: HHC GOSS HOG BIIB SSYS FBHS PBF TGP HCA LLNW October 22, 2019 11:18 AM - StreetInsider Increasing unusual put option volume: GOSS CATM BIIB HCA WEC SSYS TRV WPM HOG October 22, 2019 9:52 AM - StreetInsider Pre-Open 10/22: (BIIB) (STMP) (GNC) Higher (TTS) (TEUM) (HHC) Lower (more...) October 22, 2019 9:30 AM - StreetInsider Wall Street slips after rejection of Brexit timetable October 22, 2019 7:50 AM - StreetInsider Biogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC October 22, 2019 7:32 AM - StreetInsider Form 8-K BIOGEN INC. For: Oct 22 October 22, 2019 7:09 AM - SEC Filing Biogen (BIIB) Tops Q3 EPS by 90c October 22, 2019 6:53 AM - StreetInsider Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s Disease October 22, 2019 6:41 AM - StreetInsider Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA October 22, 2019 6:33 AM - StreetInsider Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies October 22, 2019 6:31 AM - StreetInsider Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies October 22, 2019 6:30 AM - Globe NewsWire Biogen (BIIB) IV flat into EPS and outlook October 21, 2019 10:18 AM - StreetInsider Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week October 21, 2019 7:31 AM - StreetInsider Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week October 21, 2019 7:30 AM - Globe NewsWire Biogen (BIIB) October weekly option implied volatility at upper end of range into EPS and outlook October 18, 2019 10:31 AM - StreetInsider UPDATE: BofA/Merrill Lynch Reinsates Biogen (BIIB) at Underperform October 16, 2019 4:34 PM - StreetInsider Biogen (BIIB) PT Lowered to $280 at Oppenheimer October 15, 2019 1:24 PM - StreetInsider Bernstein Reinstates Biogen (BIIB) at Market Perform October 14, 2019 7:00 AM - StreetInsider SoftBank-backed Vir Biotechnology's shares tumble in market debut October 11, 2019 1:00 PM - StreetInsider Biogen (BIIB) PT Raised to $212 at Morgan Stanley October 11, 2019 8:45 AM - StreetInsider SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO October 10, 2019 7:58 PM - StreetInsider Biogen (BIIB) Announces Landmark NURTURE Study of Infants with SMA Treated Pre-Symptomatically with SPINRAZA Published in Neuromuscular Disorders October 2, 2019 7:36 AM - StreetInsider Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders October 2, 2019 7:31 AM - StreetInsider Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders October 2, 2019 7:30 AM - Globe NewsWire Biogen (BIIB) announces Michael D. Ehlers, M.D., Ph.D., has decided to step down as EVP, Research and Development October 1, 2019 8:05 AM - StreetInsider Form 8-K BIOGEN INC. For: Sep 29 October 1, 2019 8:03 AM - SEC Filing Biogen Announces Leadership Update October 1, 2019 8:02 AM - StreetInsider Biogen Announces Leadership Update October 1, 2019 8:00 AM - Globe NewsWire Form 3 BIOGEN INC. For: Sep 19 Filed by: Galdes Alphonse September 26, 2019 5:19 PM - SEC Filing Biogen (BIIB) Reports Interferon Beta Treatments, Including PLEGRIDY (peginterferon beta-1a) & AVONEX (interferon beta-1a), Positive Receive Positive CHMP Opinion September 23, 2019 5:54 AM - StreetInsider Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding September 23, 2019 3:01 AM - StreetInsider Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding September 23, 2019 3:00 AM - Globe NewsWire Biogen (BIIB) Reports Initiation of New Global Clinical Trial, DEVOTE, Evaluating Higher Dose of SPINRAZA (nusinersen) & Additional Data September 18, 2019 7:34 AM - StreetInsider Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients September 18, 2019 7:31 AM - StreetInsider Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients September 18, 2019 7:30 AM - Globe NewsWire Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index September 17, 2019 7:31 AM - StreetInsider Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index September 17, 2019 7:30 AM - Globe NewsWire Biogen (BIIB) BG00011 Just Stopped For Toxicity, But Low Impact - RBC September 16, 2019 1:51 PM - StreetInsider S&P 500 Q2 Stock Buybacks Fall 20.1% Sequentially, 13.7% YoY September 16, 2019 11:34 AM - StreetInsider S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels September 16, 2019 11:30 AM - PR NewsWire Eisai And Biogen (BIIB) to Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease September 13, 2019 8:00 AM - StreetInsider Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease September 13, 2019 8:00 AM - PR NewsWire Biogen (BIIB) Ticks Lower on Patent News September 12, 2019 11:40 AM - StreetInsider New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum September 12, 2019 5:00 AM - Globe NewsWire New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum September 12, 2019 5:00 AM - StreetInsider Biogen (BIIB) Says New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA Over 10 Years September 11, 2019 6:23 AM - StreetInsider New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years September 11, 2019 5:01 AM - StreetInsider New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years September 11, 2019 5:00 AM - Globe NewsWire Biogen (BIIB) Competitor Likely to Post Pivotal Results Next Week - RBC Capital September 6, 2019 7:31 AM - StreetInsider Full Article List